Atherosclerosis, a disease characterized by the accumulation of lipids and inflammatory cells in the arterial wall, is a ...

Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

Maternal vitamin D status in early pregnancy is crucial for fetal growth and may reduce the risk of preterm birth, according ...

Susvimo is indicated for intravitreal use via the Susvimo eye implant only. Ranibizumab is a vascular endothelial growth ...

The company is currently preparing for Phase III trials to further assess the efficacy and safety of the agent in identifying ...

Current standard of care is a combination of drugs that target vascular growth factor receptors in order to kill tumor endothelial cells (TECs) and deprive the tumor of its blood supply in combination ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...